Drug Interactions

Mechanisms and Clinical Relevance

Jonathan E. Alpert, MD, PhD
Dorothy and Marty Silverman Department Chair
Department of Psychiatry and Behavioral Sciences
Professor of Psychiatry, Neuroscience, and Pediatrics
Montefiore Medical Center
Albert Einstein College of Medicine

Psychopharmacology 2019
Disclosures

**Speaker’s honoraria:** American Society of Clinical Psychopharmacology, American Psychiatric Association, Eli Lilly & Co., LIJ/Zucker-Hillside, Nevada Psychiatric Association, New York University, North Shore Medical Center, Organon Inc., Psicofarma, Primedia, Reed Medical Education, University of Louisville, Xian-Janssen

**Royalties:** Belvoir Publishing, Marcel Dekker, Institut la Conference Hippocrate

**Consultant fees:** Consulting Medical Associates, Luye Pharmaceuticals, PamLab LLC, Pharmavite

**Research support:** Abbott Labs, Alkermes, Aspect Medical Systems, Astra-Zeneca, Axsome Therapeutics, Bristol-Myers Squibb, Cephalon, Eli Lilly & Co., Forest Pharmaceuticals, GlaxoSmithKline, J&J Pharmaceuticals, Lichtwer Pharma, Lorex Pharmaceuticals, NARSAD, NIH, Novartis, Organon, Otsuka, PamLab LLC, PCORI, Pharmavite, Roche Laboratories, Solvay Pharma, Sanofi/Synthelabo, Wyeth-Ayerst Laboratories
Drug Interactions

- Ubiquitous polypharmacy
- Treatment of psychiatric conditions among medically ill
- Use of dietary health supplements/OTCs
- Advances in pharmacokinetics and pharmacodynamics
- Focus on preventable drug errors
- Application of bioinformatics to large populations
- Clinical decision support software in EHRs
- Combinatorial pharmacogenetic decision support tools
What are Drug-Drug Interactions?
Alterations in Drug Plasma Levels, Tissue Concentrations, and/or Drug Effects

- Associated with the use of two or more agents: prescribed, over-the-counter, and/or recreational
- In close temporal proximity: recent as well as concurrent use
Potential Consequences of Drug Interactions

- **Serious adverse events (SAEs):**
  - Delirium, cardiac arrhythmias, GI/CNS bleeding, falls, seizures, serotonin syndrome, hypertensive crises
  - SAEs related to drug-drug interactions account for up to 2-5% of all hospital admissions for patients > 55 years old

- **Increased levels/effects:**
  - Side-effects (e.g., headaches, nausea, dizziness) -> potential misdiagnosis and unnecessary medical work-ups
  - Poor tolerability -> risk to adherence

- **Reduced levels/effects:**
  - Non-response to usual doses -> relapse
  - Potential withdrawal or discontinuation emergent effects
27 yo with migraine, on propranolol, admitted with psychotic depression and treated with duloxetine (Cymbalta), bupropion (Wellbutrin) and risperidone (Risperdal).

Now c/o lightheadedness. Worse still, migraines uncharacteristically refractory to acetaminophen with codeine.

He suspects foul play.
49 yo with schizoaffective disorder receives desvenlafaxine (Pristiq) from the covering MD. She returns with confusion, diarrhea, fever and brisk reflexes.

Current meds are: aripiprazole (Abilify), lamotrigine (Lamictal), lithium and hydrochlorothiazide.

Multiple treatment trials over the past year: ziprasidone (Geodon), mirtazapine (Remeron), selegiline (Emsam), and esketamine
32 yo with OCD, bipolar disorder, asthma, and GERD presents with grand mal sz days after switching from clomipramine (Anafranil) to fluvoxamine (Luvox).

Other meds: clozapine, lithium, theophylline, omeprazole, and prednisone.
Case 4

Agitated and incoherent 67 yo with schizophrenia brought in by police. Meds: olanzapine (Zyprexa), mirtazapine (Remeron), and diphenhydramine (Benadryl).

Doxepin (Sinequan) recently added for atopic dermatitis.
Case 5

52 year old with panic disorder, refractory depression, and chronic insomnia, presents with dizziness, drowsiness, nausea and slurred speech.

Meds: alprazolam (Xanax), eszopiclone (Lunesta), quetiapine (Seroquel) and vilazodone (Viibryd). Recreational cannabis. Recently started on clarithromycin (Biaxin) for sinusitis. Trying to stay well-hydrated with fruit juice.
Case 6

37 yo with MDD, GAD, atypical facial pain. Meds: escitalopram (Lexapro), clonazepam, and an OCP.

Recently switched from gabapentin (Neurontin) to carbamazepine (Tegretol). Modafinil (Provigil) added to offset sedation. Offered St. John’s Wort by friend.

Cancels appt this a.m. due to nausea and malaise.
Drug Interaction Errors

- **Type 1**
  - Failure to anticipate
  - Failure to recognize

- **Type 2**
  - Phobic avoidance
  - Therapeutic paralysis
Navigating between denial and paralysis

What next?...

• General precepts
• Classification and mechanisms
• Drug interactions worth knowing
• Case vignettes revisited

Scylla and Charybdis
Interactions are ubiquitous but...

- Serious adverse interactions are uncommon
- Absolute contra-indications are rare
In addition to drug interactions, multiple factors influence inter-individual variability in response to drugs including:

- Treatment adherence
- Age
- Gender
- Nutritional status
- Smoking/ETOH
- Disease states
- Genetic polymorphisms
Consider the True Weight of Evidence

• Inference is often used to fill in gaps in data

• As of 2006, there were over 520 quadrillion possible combinations of up to five drugs on a patient’s drug regimen yet only 700 drug interactions studies in the literature...

• More studies exist in 2019 but also there are more drugs and possible drug combinations.

• Virtually all published studies are concerned with the “simplest” case (Drug B’s impact on Drug A’s levels or effects) rather than with the more complex, multiple polypharmacy used in real-world clinical settings.

Preskorn and Flockhart, Primary Psychiatry 13:35 64, 2006
Drug interaction warnings are often based on extrapolation from in vitro or animal studies or based on drug interactions in humans involving related but different drugs

- In vitro studies
- Animal studies
- Controlled human pharmacokinetic studies
- Case reports
- Post-marketing surveillance
  - FDA Adverse Event Reporting System (AERS)
  - Health care system databases
- Epidemiological studies
Consider the Clinical Context

Higher level of concern about potential drug interactions whenever:

- Using drugs with a narrow therapeutic window (e.g., cyclosporine), low therapeutic index (e.g., digoxin), potential for catastrophic side-effects (e.g., MAOIs)
- Evaluating patients who present with perplexing clinical presentations, outcomes, or levels
- Treating “brittle” patient populations for whom even small variations in drug effects/levels may pose hazards
- Embarking on (worthy) efforts to simplify (“deconstruct”) a complex regimen
Focus on the most important (i.e., common and/or potentially catastrophic) interactions

Interaction checker resources are widely available:

- **Open Access**
  - Drugs.com
  - Medscape (WebMD)
  - Epocrates (Athenahealth)

- **By Subscription**
  - Lexicomp (Wolters Kluwer) - included in UpToDate
  - Clinical Pharmacology - ClinicalKey (Elsevier)
  - Micromedex (IBM)

- **Clinical Decision Support Systems** increasingly standard in Electronic Health Records (EHRs) and Computerized Physician Order Entry systems (CPOEs), albeit with low thresholds for flagging interactions -> “alert fatigue”

*Caveat emptor:* inter-rater agreement on potential DDIs across available drug interaction databases is strong (kappa > 0.6) for drug interactions classified as “severe” but only fair (kappa < 0.3) for drug interactions considered “moderate” (Monteith S, Glenn T *Psychiatry Research* 275:366-372, 2019) - to dig deeper, check more than one of the resources + consider lit search of original references
Not always a negative; can be leveraged therapeutically

• Management of overdose
  • e.g. naloxone (opiates); flumazenil (benzodiazepines); acidifying urine (amphetamines, cocaine)

• Treatment of side-effects
  • e.g. anticholinergic rx for EPS; 5HT-3 blockade of nausea on SSRI or SNRIs

• Augmentation of response
  • e.g. mirtazapine+venlafaxine

• Boosting of drug levels/prolongation of drug action
  • e.g. cyclosporine by ketoconazole or grapefruit juice; olanzapine by fluvoxamine
Classification of Drug Interactions

- Pharmacodynamic
- Pharmacokinetic
- Mixed
- Idiosyncratic
Pharmacodynamic Interactions

Alterations in pharmacological effects produced:

• directly by interactions at a common biological site (receptor) (e.g. clonidine and yohimbine at $\alpha_2$-adrenergic receptor; pramipexol [Mirapex] and risperidone at D2 receptor; naltrexone and buprenorphine at the $\mu$ opioid receptor)

• indirectly through separate but interrelated biological sites (e.g., haloperidol + benztropine)
Pharmacokinetic Drug Interactions

Alterations in plasma levels and/or tissue concentrations produced by interactions that influence at least one of the following four processes (“ADME”):

• Absorption
• Distribution
• Metabolism
• Excretion
Mixed Drug Interactions

Interactions believed to involve both a pharmacokinetic and pharmacodynamic component:

Examples:

**Serotonin toxicity on paroxetine and dextromethorphan:** paroxetine inhibits metabolism of dextromethorphan leading to increased levels of dextromethorphan (pharmacokinetics) plus both drugs exert serotonergic effects (pharmacodynamics).

**Increased bleeding risk on fluoxetine and warfarin:** Fluoxetine inhibits metabolism of S-warfarin by P450 2C9 thereby prolonging INR (pharmacokinetics); plus SSRIs may reduce platelet aggregation, thereby increasing bleeding diathesis along with warfarin (pharmacodynamics).
Idiosyncratic Drug Interactions

*Sporadic* interactions that occur in a small number of individuals and are *not yet* predicted from known pharmacodynamic or pharmacokinetic properties of the drugs.

Example: sporadic neurotoxicity on lithium and antipsychotics
Pharmacokinetic Interactions

More about the four key pharmacokinetic mechanisms (ADME)...

Absorption  Distribution  Metabolism  Excretion
Interactions involving drug absorption are generally less important than interactions affecting drug clearance (metabolism, excretion).

Absorption interactions may alter time to reach maximum drug concentration ($T_{\text{max}}$) and/or may alter the maximum drug concentration achieved ($C_{\text{max}}$).

AUC = area under the curve
Absorption

Decreased Absorption:

- Charcoal, antacids, kapolin-pectin, cholestyramine, fatty acid substitutes, orlistat may bind to drug and form unabsorbable complexes.

Increased Absorption:

- **Drugs that speed gastric emptying** (e.g. metoclopramide, cisapride [Propulsid]) or **inhibit intestinal motility** (e.g. TCAs, morphine, marijuana) may promote greater contact with absorptive mucosal surface of upper portion of small intestine.

- **Drugs that Inhibit gut enzymes** (including MAO and P450 3A4 enzymes) may increase amount of relevant substrate (e.g. tyramine) reaching portal circulation.
Variable Drug Interactions with Food

- Increased absorption of ziprasidone or lurasidone with food
- Decreased bioavailability of thyroxine with food (particularly with calcium and iron containing foods and supplements, coffee, soy and fiber)
- Decreased absorption of nicotine (e.g., gum) in presence of acidic foods/beverages (e.g., coffee, juices, soda)
Distribution

- Regional blood flow
- Lipophilicity
- Adipose/lean body mass
- Protein binding
- Drug transport proteins (e.g. P-glycoprotein [Pgp])
Protein Binding

*Competition* for protein-binding sites by two or more drugs resulting in *displacement* of previously bound (inactive) drug which in unbound form is now active.

*Equilibration occurs* as unbound form is also now available for redistribution to tissues and elimination.
<table>
<thead>
<tr>
<th>Drug</th>
<th>% Bound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lithium</td>
<td>&lt; 3%</td>
</tr>
<tr>
<td>Gabapentin [Neurotonin]</td>
<td>&lt; 3%</td>
</tr>
<tr>
<td>Pregabalin [Lyrica]</td>
<td>&lt; 3%</td>
</tr>
<tr>
<td>Levomilnacipran [Fetzima]</td>
<td>&lt; 15%</td>
</tr>
<tr>
<td>Acamprosate [Campral]</td>
<td>&lt; 20%</td>
</tr>
<tr>
<td>Topiramate [Topamax]</td>
<td>&lt; 20%</td>
</tr>
<tr>
<td>Levomilnacipran [Fetzima]</td>
<td>&lt; 25%</td>
</tr>
<tr>
<td>Venlafaxine, desvenlafaxine</td>
<td>&lt; 30%</td>
</tr>
<tr>
<td>Zonisamide [Zonegran]</td>
<td>&lt; 40%</td>
</tr>
<tr>
<td>Memantine [Namenda]</td>
<td>&lt; 40%</td>
</tr>
<tr>
<td>Lamotrigene [Lamictal]</td>
<td>&lt; 60%</td>
</tr>
</tbody>
</table>

*Very unlikely to be involved in protein binding interactions*
Metabolism (2 Phases)

Phase I Reactions

- Oxidation, reduction, hydrolysis
- Often rate-limiting
- Produce potentially active metabolites subject to Phase II metabolism
Phase II Reactions

- Conjugation, acetylation

- Produce typically *inactive metabolites* which are highly polar, water soluble, ready for renal excretion

- Some agents undergo Phase II metabolism only (e.g. valproate, lorazepam, oxazepam, temazepam)
Metabolism of a Substrate* may be Inhibited or Induced**,***,

**Inhibition**
- **Rapid** impact; substrate **levels rise** quickly
- Mechanisms: competitive inhibition (displacement of substrate); **covalent binding** (conformational change of enzyme); **enzyme destruction** (e.g., phytochemicals of grapefruit juice may destroy P450 3A4, in addition to other mechanisms of inhibition)

**Induction**
- **Gradual** impact; substrate **levels decline** slowly
- Mechanism: up-regulation of transcription; enhanced synthesis of metabolic enzyme

* **Substrate** = a drug metabolized by a given enzyme.
** **Inhibitor or inducer** = a drug that alters the metabolic activity of that enzyme.
***A drug can be a substrate for a given enzyme and an inhibitor or inducer of that enzyme or another enzyme
### Clinically Relevant Inducers

<table>
<thead>
<tr>
<th>Drug</th>
<th>Inducer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td></td>
</tr>
<tr>
<td>Phenobarbital</td>
<td><em>Chronic</em> alcohol</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Chronic smoking</td>
</tr>
<tr>
<td>Primidone</td>
<td>Charbroiled meats</td>
</tr>
<tr>
<td>Prednisone</td>
<td>Cruciferous vegetables</td>
</tr>
<tr>
<td>Ritonavir (chronic)</td>
<td>St. John’s Wort</td>
</tr>
</tbody>
</table>
“Red Flags”: Think Inhibition When You See...

Clinically Relevant Inhibitors

<table>
<thead>
<tr>
<th>Antifungals (azoles)</th>
<th>SSRIs</th>
<th>Acute alcohol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrolide antibiotics</td>
<td>Phenothiazines</td>
<td>Cimetidine</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>Valproic acid</td>
<td>Quinidine</td>
</tr>
<tr>
<td>Antiretrovirals</td>
<td>Nefazodone</td>
<td>Ca++ ch. blockers</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>Duloxetine</td>
<td>Grapefruit juice</td>
</tr>
<tr>
<td>Antimalarials</td>
<td>Bupropion</td>
<td>Propafenone</td>
</tr>
<tr>
<td>Disulfiram</td>
<td>β-blockers</td>
<td>Amiordarone</td>
</tr>
</tbody>
</table>
Cytochrome P450 Isoenzymes

- Heterogeneous group of over 50 heme-containing oxidative enzymes (in humans), located predominantly in the endoplasmic reticulum of hepatocytes (also brain, gut)
- Over 500 P450 isoenzymes across all species
- Responsible for Phase I metabolism of a wide variety of endogenous and xenobiotic substrates (fatty acids, prostaglandins, steroids, carcinogens/pro-carcinogens, toxins).
- Involved in metabolism of > 80% of all available drugs
Cytochrome P450 Isoenzymes

Of the enzymes elucidated, those most relevant to drug metabolism and interactions are:

- 1A2
- 2C subfamily
- 2D6
- 3A subfamily
CYP 450 Polymorphisms

Genetically based differences in enzyme structure (isoforms) resulting in altered activity.

Known polymorphisms among CYP 450 isoenzymes include:

- 2C19 (gene on chromosome 10)
- 2D6 (gene on chromosome 22)

Steadily evolving knowledge on hundreds of alleles for common P450 isoenzymes (cf. www.imm.ki/CYPalleles/)
CYP 450 Polymorphisms

Bimodal distribution of isoforms results in:

➢ Extensive metabolizers EMs (normal activity)

➢ Poor metabolizers PMs

Small numbers of “ultra-rapid metabolizers” UMs (more than usual complement of active enzyme)

Small number of individuals with partially functional enzyme, intermediate between extensive and poor.
Extensive vs. Poor Metabolizers

**Extensive** *(Normal)*
- Susceptible to **normal degrees of induction or inhibition** with inducers and inhibitors
- Convert to poor metabolizers functionally in presence of an inhibitor of the enzyme
- Convert to ultra-rapid metabolizers functionally in presence of an inducer of the enzyme

**Poor**
- Relatively insensitive to induction and inhibition
- Higher baseline concentrations of parent drug and lower levels of metabolite
- Exaggerated effects of drugs at low doses (e.g., with TCAs)
- Or diminished effects if the parent drug is a *pro-drug* that must be converted to an active form (e.g., with codeine, tramadol or tamoxifen) *via* that enzyme
Considerable diversity of metabolic enzymes beyond the CYP 450 enzymes
Non-CYP 450 Metabolic Enzyme Systems involved in Drug Metabolism

- Flavin-containing monooxygenases (FMOs):
  - At least 5 isoenzyme families in humans

- Uridine diphosphate-glucuronosyl-transferases (UGTs):
  - UGT 1 and UGT 2 subfamilies most important for drug metabolism in humans

- Methyltransferases:
  - Numerous families involved in methylation reactions e.g., catechol O-methyltransferase (COMT)

- Sulfotransferases:
  - Responsible for sulfation of many endogenous substances and drugs
Drugs are often metabolized through more than a single enzyme or enzyme family...

Examples:

- Tertiary TCAs (e.g. amitriptyline) via P450 1A2, 2C, 2D6, and 3A
- Olanzapine via CYP450 1A2, UGTs and FMOs
Inhibitors of one pathway may induce another and/or have mixed effects...

- Modafinil and armodafinil inhibit P450 2C subfamily but induce P450 3A subfamily and 1A2.
- Ritonavir [Norvir] inhibits P450 2D6 and 3A4 with acute administration, but induces glucuronosyltransferase (and may induce P450s with chronic use).
Drug Excretion

Practical significance for drug-drug interactions is mainly for drugs which are not hepatically metabolized (e.g. lithium, gabapentin, pregabalin), or in the presence of disease states (e.g. renal, hepatic insufficiency) or with management of overdose (where changing urine pH may alter renal excretion of acidic or basic agents)

Related terms: drug elimination = all processes that result in clearance of drug from body including liver metabolism, renal excretion, and excretion into bile and sweat.
Nominations for the...

Top 10 Drug Interactions involving Psychotropic Medications
Hypertensive Crises:

• With sympathomimetics
  - includes OTCs (pseudoephedrine, phenylephrine, oxymetazoline [Afrin])
  - Involves inhibition of MAO-A primarily (hence selegiline [Emsam] at < 6 mg/24h patch less risk, affecting MAO-B mainly; at higher doses is non-specific for MAO-A and MAO-B)
  - Potential increased risk of BP elevation with esketamine + MAOIs
Serotonin Syndrome:

- *With meperidine [Demerol] – ABSOLUTE contraindication !!!*

- Other narcotics with serotonergic properties (e.g. tramadol [Ultram]) have rarely caused problems.

- Codeine, morphine are generally safer, though may be potentiated by MAOIs; use with caution
#1 MAOI Interactions

Serotonin Syndrome

• With other highly serotonergic agents:

Other MAOIs, SSRIs, SNRIs, and atypical antidepressants (nefazodone, mirtazapine), L-tryptophan, dextromethorphan, sumatriptin (Imitrex), sibutramine (Meridia), buspirone, carbamazepine, lithium, dihydroergotamine, St. John’s Wort, VMAT2 inhibitors
#1 MAOI Interactions

- **Serotonin Syndrome/Serotonin Toxicity:**
  Often rapidly developing within hours; often no unique lab findings (unlike Neuroleptic Malignant Syndrome)

- **SSRIs+MAOIs are absolutely contraindicated**
  - Must wait 4-5 elimination half-lives after SSRIs or other serotonergic agents before; 4-5 starting MAOIs; 4-5 weeks for fluoxetine (norfluoxetine).
  - Must wait 2 wks after MAOI before starting SSRI or other serotonergic agents to allow MAO to regenerate
# Serotonin Syndrome: Hunter Criteria

## Hunter Serotonin Toxicity Criteria: Decision Rules

In the presence of a serotonergic agent:

1. IF (spontaneous clonus = yes) THEN serotonin toxicity = YES
2. ELSE IF (inducible clonus = yes) AND [(agitation = yes) OR (diaphoresis = yes)] THEN serotonin toxicity = YES
3. ELSE IF (ocular clonus = yes) AND [(agitation = yes) OR (diaphoresis = yes)] THEN serotonin toxicity = YES
4. ELSE IF (tremor = yes) AND (hyperreflexia = yes) THEN serotonin toxicity = YES
5. ELSE IF (hypertonic = yes) AND (temperature > 38°C) AND [(ocular clonus = yes) OR (inducible clonus = yes)] then serotonin toxicity = YES
6. ELSE serotonin toxicity = NO

### ANY OF THE FOLLOWING SETS (A-E)

- (A) Spontaneous clonus
- (B) Inducible clonus plus agitation or diaphoresis
- (C) Ocular clonus plus agitation or diaphoresis
- (D) Tremor plus hyperreflexia
- (E) Hypertonicity plus fever plus ocular clonus or inducible clonus

---

Dunkley E et al. QJM 2003;96:635-642
#2 Lithium Interactions

Increased Lithium Levels with:

- Thiazide diuretics
- ACE inhibitors (captopril, enalapril)
- Angiotensin II receptor antagonists (valsartan, losartan)
- Prescription strength NSAIDs (except ASA, sulindac), COX-2 inhibitors
- Metronidazole, tetracycline, spectinomycin
#2 Lithium Interactions

**Decreased Lithium Levels with:**

- Aminophylline, theophylline
- Urinary alkalinization (acetazolamide, sodium bicarbonate)
- Sodium chloride
- Osmotic diuretics (mannitol)
Potential consequences...

- Increased levels of TCAs, β-blockers (lipophilic – including propranolol and metoprolol but NOT atenolol or nadolol), antiarrhythmics, phenothiazines (e.g., thioridazine), atypical antipsychotics (e.g., aripiprazole, iloperidone), valbenazine

- Inhibited conversion of pro-drugs including tamoxifen, codeine and tramadol to active forms
# SSRIs, SSNRIss and P450 2D6 Inhibition

<table>
<thead>
<tr>
<th>SSRI/SNRI</th>
<th>1A2</th>
<th>2C</th>
<th>2D6</th>
<th>3A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoxetine</td>
<td>-</td>
<td>++</td>
<td>++++(+++++)</td>
<td>+</td>
</tr>
<tr>
<td>Sertraline</td>
<td>-</td>
<td>+ (+)</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>-</td>
<td>-</td>
<td>++++</td>
<td>-</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>++++</td>
<td>++</td>
<td>-</td>
<td>+++</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Citalopram</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Vilazodone</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>-</td>
<td>-</td>
<td>(+)</td>
<td>-</td>
</tr>
<tr>
<td>Desvenlafaxine</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>-</td>
<td>-</td>
<td>+++</td>
<td>-</td>
</tr>
<tr>
<td>Levomilnacipran</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vortioxetine</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

+ = inhibition  
() = metabolite effect
### Other Antidepressants and P450 Inhibition

<table>
<thead>
<tr>
<th>Drug</th>
<th>1A2</th>
<th>2C</th>
<th>2D6</th>
<th>3A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupropion</td>
<td>-</td>
<td>-</td>
<td>++++</td>
<td>-</td>
</tr>
<tr>
<td>Nefazodone</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>++++</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Reboxetine</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>St. John’s Wort</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>---</td>
</tr>
</tbody>
</table>

--- = suspected induction
CYP450 2D6

**Substrates**
Amphetamine, aripiprazole, atomoxetine, beta-blockers (lipophilic; including propranolol, metoprolol, carvedilol and nebivolol), brexpiprazole, codeine, debrisoquine, deutetrabenazine, dextromethorphan, diltiazem, donepezil, dextromethorphan, duloxetine, encainide, flecainide, galantamine, haloperidol, hydroxycodone, iloperidone, lidocaine, metaclopramide, mexilitene, mCPP, nifedipine, odansetron, oxycodon, phenothiazines (e.g., thioridazine, perphenazine), propafenone, risperidone, SSRIs, tamoxifen, TCAs, tramadol, trazodone, valbenazine, venlafaxine, vortioxetine

**Inhibitors**
Amiodarone, antimalarials, bupropion, cannabidiol, cimetidine, duloxetine, fluoxetine, hydroxyzine, mibefradil, methadone, metoclopramide, moclobemide, nelfinavir, paroxetine, phenothiazines, quinidine, ritonavir, sertraline, terbinafine, TCAs, THC, yohimbine

**Inducers**
Dexamethasone, Rifampin
Potential consequences…

- Altered levels of numerous key substrates
  - e.g., carbamazepine, cyclosporine, opiates, calcium channel blockers, pimozide, ketamine, statins, OCPS, valbenazine, THC and cannibidiol (CBD)
- Increased pimozide may cause arrhythmias;
- Increased carbamazepine may cause delirium, seizures
- Increased methadone, oxycodone, fentanyl may cause respiratory depression
- Decreased methadone, buprenorphine may cause withdrawal

Common inhibitors include fluvoxamine, fluoxetine and nefazadone (increase levels of 3A substrates)
Common inducers include carbamazepine, modafinil and armodafinil, St. John’s Wort (decrease levels of 3A substrates)
CYP450 3A Subfamily

**Substrates**
Alfentanil, alprazolam, amiodarone, amprenavir, aripiprazole, brexipiprazole, bromocriptine, buprenorphine, buspirone, calcium channel blockers, caffeine, cannabidiol, carbamazepine, cisapride, cocaine, clozapine, cyclosporine, diazepam, disopyramide, efavirenz, estradiol, eszopiclone, fentanyl, guanafacine, iloperidone, indinavir, HMG-CoA reductase inhibitors (lovastatin, simvastatin), ketamine, levomilnacipran, lidocaine, loratadine, lurasidone, methadone, midazolam, nimodipine, pimozide, prednisone, progesterone, propafenone, quetiapine, quinidine, ramelteon, ritonavir, sildenafil, suvorexant, tacrolimus, testosterone, tertiary TCAs, THC, trazodone, triazolam, valbenazine, vardenafil, vilazodone, vinblastine, warfarin, zolpidem, zaleplon, ziprasidone

**Inhibitors**
Antifungals, calcium channel blockers, cimetidine, efavirenz (also inducer), indinavir, fluvoxamine, fluoxetine (norfluoxetine), fosamprenavir, grapefruit juice, macrolide antibiotics, mibefradil, nefazodone, nelfinavir, norfloxacin, ritonavir

**Inducers**
Armodafinil, carbamazepine, efavirenz (also inhibitor), glucocorticoids, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, ritonavir (chronic), St. John’s Wort, troglitazone
#5 Carbamazepine [Tegretol] Induction of Metabolism

- Reduces levels of many CNS acting agents (including itself; “auto-induction”) and many non-psychotropics (e.g., OCPs, cyclosporine, calcium channel blockers) via P450 3A induction and other mechanisms
- Conversely, discontinuation may result in drug toxicity as levels of other drugs rise due to lifting of inducing influence
- Oxcarbazepine and topiramate can also induce metabolism of other agents, generally to lesser extent
Potential consequences...

- Toxicity on clozapine, asenapine, duloxetine, theophylline, thioridazine and other 1A2 substrates
- Increased clozapine, theophylline may cause seizures
- Increased thioridazine may cause arrhythmias
CYP450 1A2

Substrates
Acetaminophen, aminophylline, asenapine, estradiol, caffeine, clozapine, cyclobenzaprine, fluvoxamine, haloperidol, mirtazapine, odansetron, olanzapine, phenacetin, procarciniogens, riluzole, ropinirole, tacrine, tertiary tricyclic antidepressants, theophylline, R-warfarin, zileuton, zolmitriptan

Inhibitors
Amiodarone, fluoroquinolones, fluvoxamine, cimetidine, grapefruit juice, methoxsalen, ticlopidine

Inducers
Armodafinil, charbroiled meats, cruciferous vegetables, insulin, omeprazole, modafinil, ritonavir, smoking (cigarettes, marijuana)
Potential for...

- Additive/synergistic anti-histamine, anti-muscarinic, anti-\(\alpha_1\)-adrenergic and quinidine-like effects
#8 Oral Contraceptives

- Many psychotropics induce metabolism of OCPs (estrogen component) including carbamazepine, oxcarbazepine, phenobarbital, phenytoin, and high dose topiramate, St. John’s Wort and modafinil and armodafinil
  - Second form of contraception required and/or dose increase if used for other purposes when these agents are added to an OCP regimen
- Reciprocally OCPs may induce metabolism of lamotrigine and valproate, thereby reducing levels of these anticonvulsants by as much as 50%
  - Anticipated dose increase for lamotrigine; possibly for valproate (therapeutic drug monitoring is needed after OCP added)
#9 Valproate Inhibition of Metabolism

Increased levels of:

- Lamotrigine (with increased risk of Stevens-Johnson, Toxic Epidermal Necrolysis, and other serious rashes)
- Carbamazepine 10,11-epoxide metabolite (with CNS activity/risk of toxicity)
- Tricyclic antidepressants (amitriptyline, nortriptyline, clomipramine)
- Anti-neoplastic drugs (cisplatin, etoposide)
#10: Increased Bleeding Risk with SSRIs and Other Agents

- Best documented with risk of upper GI bleeding on SSRIs+high dose NSAIDs as well as SSRIs+Warfarin
- Risk of SSRIs + aspirin less well elucidated.
- Proton pump inhibitors and H2 blockers may be somewhat protective
- Other bleeding risks (e.g., CNS) suspected in some populations
CYP450 2C Subfamily

Substrates
Barbiturates, bortezomib, cannabidiol, celecoxib, diazepam, fluvastatin, glipizide, glyburide, irbesartan, losartan, mephenytoin, NSAIDs, nelfinavir, phenytoin, primidone, propranolol, proguanil, proton pump inhibitors, rosiglitazone, rosuvastatin, tamoxifen, tertiary TCAs, THC, tolbutamide, S-warfarin, R-warfarin

Inhibitors
Amiodarone, Armodafinil, chloramphenicol, efavirenz, felbamate, fluoxetine, fluvoxamine, isoniazide, ketoconazole, lansoprazole, modafinil, omeprazole, oxcarbazepine, pantoprazole, ritonavir, sertraline, sulfamethoxazole, ticlopidine, topiramate, zafirlukast

Inducers
Carbamazepine, norethindrone, phenytoin, prednisone, rifampin
Homestretch -- Back to the Cases to Wrap Up!
A Case of P450 2D6 Inhibition

27 yo with migraine, on propranolol, admitted with psychotic depression and treated with duloxetine (Cymbalta), bupropion (Wellbutrin) and risperidone (Risperdal)...

• **Lightheadedness**; *propranolol* metabolism impeded via 2D6 inhibition by *duloxetine and bupropion* -- levels rise

• **Migraines refractory** to acetaminophen with codeine; pro-drug *codeine* no longer biotransformed into active form by 2D6
A Case of MAOI-SNRI Interaction

49 year old with schizoaffective disorder receives desvenlafaxine (Pristiq) from the covering MD. Presents with confusion, diarrhea, fever and brisk reflexes. Current meds are: aripiprazole (Abilify), lamotrigene (Lamictal), lithium and hydrochlorothiazide. Multiple other treatment trials over the past year....

- **Serotonin syndrome** as MAOI selegiline (Emsam) discontinued only 8 (not 14) days before desvenlafaxine (Pristiq)
A Case of P450 1A2 Inhibition

32 yo with OCD, bipolar disorder, asthma, and GERD presents with grand mal sz days after switching from clomipramine (Anafranil) to fluvoxamine (Luvox). Other meds: clozapine, lithium, theophylline, omeprazole, and prednisone taper...

• Clozapine and theophylline toxicity  Clozapine and theophylline levels rise steeply in setting of P450 1A2 inhibition by fluvoxamine -- seizure threshold rapidly lowered
Agitated and incoherent 67 yo with schizophrenia brought in by police. Meds: *olanzapine* (Zyprexa), mirtazapine (Remeron), and *diphenhydramine*; *doxepin* (Sinequan) recently added for atopic dermatitis...

- **Anticholinergic delirium** *doxepin* added to already high burden of anticholinergic drug effects in an older, susceptible patient already on other medications with anti-muscarinic effects including *diphenhydramine* and *olanzapine*
A Case of P450 3A Inhibition

52 year old with panic disorder, resistant depression, and chronic insomnia presents with dizziness, drowsiness, nausea, and slurred speech. Meds: *alprazolam* (Xanax), *eszopiclone* (Lunesta), *quetiapine* (Seroquel), and the vilazodone (Viibryd). Recreational *cannabis*. She was recently started on *clarithromycin* (Biaxin) for sinusitis.

She’s trying to stay well-hydrated (*with grapefruit juice*)...

- **Rapidly rising levels of four P450 3A substrates** with CNS and GI side-effects in setting of 3A inhibition by *macrolide antibiotic* and *grapefruit juice*
A Case of Induction of OCP Metabolism

37 yo with MDD, GAD, atypical facial pain. Meds: escitalopram (Lexapro), clonazepam, and an OCP; switched from gabapentin (Neurontin) to carbamazepine (Tegretol) for pain. Modafinil (Provigil) added to offset sedation. Offered St. John’s Wort by a friend. Cancels appt w/malaise...

• Unanticipated pregnancy in setting of reduced OCP levels/efficacy on carbamazepine, modafinil and St. John’s Wort
Parting Reflections

- **Maintain perspective:** Drug interactions involving psychiatric medications are ubiquitous, though few absolute contraindications. Many factors influence drug response; drug interactions are among them.

- **Become familiar with key interactions:** numerous resources exist for looking up others

- **Navigate between denial and therapeutic paralysis:**
  - Patients rely on us to minimize risk of side-effects and toxicity though equally count on our resourcefulness to help achieve their best outcomes

- **Celebrate the fire hose:** integral part of the lifelong learning and expertise we can bring to patient care